KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Average (2016 - 2025)

Historic Equity Average for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Q3 2025 value amounting to $99.8 million.

  • Rigel Pharmaceuticals' Equity Average rose 54790.8% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 54790.8%. This contributed to the annual value of -$12.7 million for FY2024, which is 4000.0% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Equity Average stood at $99.8 million for Q3 2025, which was up 54790.8% from $50.3 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Equity Average peaked at $99.8 million during Q3 2025, and registered a low of -$30.8 million during Q2 2024.
  • Its 5-year average for Equity Average is $9.8 million, with a median of -$5.7 million in 2024.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Equity Average plummeted by 177805.19% in 2023, and later surged by 54790.8% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Equity Average (Quarter) stood at $40.0 million in 2021, then crashed by 141.79% to -$16.7 million in 2022, then crashed by 80.8% to -$30.2 million in 2023, then skyrocketed by 81.24% to -$5.7 million in 2024, then soared by 1858.4% to $99.8 million in 2025.
  • Its Equity Average was $99.8 million in Q3 2025, compared to $50.3 million in Q2 2025 and $10.9 million in Q1 2025.